

CURRICULUM VITAE

CATHERINE (CATHY) M. TANGEN

1. PERSONAL DATA

SWOG Statistics & Data Management Center
Public Health Division
Fred Hutchinson Cancer Center
1100 Fairview Avenue N, M3-C102
Seattle, WA 98109-1024
W: (206) 667-2933
ctangen@fredhutch.org

2. EDUCATION

1985 University of Washington, B.S. (Zoology)
1990 University of North Carolina, M.S. (Biostatistics)
1997 University of North Carolina, Dr.P.H. (Biostatistics)

3. POSTGRADUATE TRAINING

N/A

4. FACULTY POSITIONS HELD

1999-2004 Assistant Professor, Public Health Sciences, SWOG, Fred Hutch
2004-2008 Associate Professor, Public Health Sciences, SWOG, Fred Hutch
2008- Professor, Public Health Sciences, SWOG, Fred Hutch
2009-2015 Affiliate Professor, Department of Biostatistics, University of Washington, Seattle, WA

5. HONORS

N/A

6. RESEARCH FUNDING

A. Active

2019-2025	Sponsor: NIH U10 CA180819 (LeBlanc) Title: SWOG Statistics and Data Management Center (SDMC) Total Costs: \$79,863,373 Role: Deputy Director
2019-2025	Sponsor: NIH UG1CA189974 (Tangen) Title: SWOG NCORP Research Base Total Costs: \$14,500,828 Role: m-PI
2019-2027	Sponsor: SWOG CTP (Tangen) S1806 (Tangen) Title: SWOG S1806 "Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer" Total Costs: \$2,000,994<<no change Role: Consortium PI
2019-2025	Sponsor: NIH 2 U01CA182883 (Tangen) Title: PCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research Total Costs: \$10,557,226 Role: co-PI
2022-2024	Sponsor: SWOG CTP (LeBlanc)

Title: Startup effort on CTP preferred Partnership trials
 Total Costs: \$583,336
 Role: Faculty Statistician

2022-2024 Sponsor: The Regents of the University of California (Tangen)
 Title: Serum Markers of Bone Metabolism in Metastatic Prostate Cancer
 Patients on CYP-17 Inhibitor Therapy (S1216)
 Total Costs: \$34,483
 Role: Consortium PI

B. Pending

C. Past

2018-2023 Sponsor: NIH R01CA222833-01A1 (Dai)
 Title: Statistical Genetics and Genomics for Epidemiologic Research
 Role: Co-investigator

2017-2021 Sponsor: SWOG CTP S1605 (Tangen)
 Title: SWOG S1605 “A Phase II Trial of Atezolizumab in BCG
 Unresponsive Non-Muscle Invasive Bladder Cancer”
 Role: Consortium PI

2013-2019 Sponsor: NIH 5UM1CA182883-05 (Tangen)
 Title: PCPT And Select Cohorts: Core Infrastructure Support For Cancer Research
 Role: m-PI

2005-2010 Sponsor: NIH 1 P01 CA108964-01A1 (Lippman)
 Title: Biology of Prostate Cancer Prevention Trial
 Role: Consortium PI

2010-2013 Sponsor: NIH R01 CA138639 (Neuhouser)
 Title: Vitamin D and Prostate Cancer: Biomarkers & Genetic Variation
 Role: Co-investigator

1983-2012 Sponsor: NIH 5U10CA037429 (Baker, Coltman)
 Title: CCOP Research Base, PCPT/PCPT LTFU, And Select Programs
 - Prostate Cancer Prevention Trial (PCPT)
 Role: Consortium PI 2002-2012
 - PCPT Long Term Follow Up (PCPT LTFU)
 Role Consortium PI 2004-2012

7. BIBLIOGRAPHY

15. BIBLIOGRAPHY For Publications in Refereed Journals, please specify if [original work], [review], etc.

a. Publications in refereed journals – original work unless otherwise specified

1. Koch, GG, **Tangen CM**, Tudor GM, Stokes ME. Comment on a critical look at accumulation analysis and related methods. *Technometrics* 32:137-149, 1990.
2. Sloane PD, Matthew LJ, Scarborough M, Desai JR, Koch GG, **Tangen CM**. Physical and pharmacological restraint of nursing home patients with dementia - impact of specialized units. *JAMA* 13:1278-1282, 1991.

3. Bukowski RM, **Tangen CM**, Lee R, Macdonald JS, et al. Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: A Southwest Oncology Group Study. *J Clin Oncol* 10:1914-1918, 1992.
4. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, **Tangen C**. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. *JAMA* 270:943-947, 1993.
5. Leichman CG, **Tangen CM**, Macdonald JS, Leimert T, Fleming TR. Phase II trial of amonafide in advanced pancreas cancer: A Southwest Oncology Group study. *Invest New Drugs* 11:219-221, 1993
6. Berenberg JL, **Tangen C**, Macdonald JS, Barlogie B, Laufman LR. VM26 in gastric cancer: A Southwest Oncology Group study. *Invest New Drugs* 11:333-334, 1993
7. Jenkins TR, **Tangen C**, Macdonald JS, Weiss, Chapman R, Hantel A. A phase II trial of piroxantrone in adenocarcinoma of the pancreas: A Southwest Oncology Group study. *Invest New Drugs* 11:329-331, 1993.
8. Bukowski RM, **Tangen CM**, Peterson RF, Taylor SA, Rinehart JJ, Eyre HJ, Rivkin SE, Fleming TR, Macdonald JS. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid: A Southwest Oncology Group study. *Cancer* 73:1505-1508, 1994.
9. Hantel A, **Tangen C**, Gluck WL, Macdonald JS. Phase II trial of piroxantrone in gastric carcinoma: A Southwest Oncology Group study. *Invest New Drugs* 12:159-161, 1994.
10. Hantel A, **Tangen CM**, Macdonald JS, Richman SP, Pugh, RP, Pollock, T. Phase II trial of trimetrexate in untreated advanced gastric carcinoma. *Invest New Drugs* 12:155-157, 1994
11. Marshall ME, **Tangen CM**, Berenberg JL, Balcerzak SP, Brown T, Macdonald JS. Treatment of advanced colorectal carcinoma with 5-fluorouracil, leucovorin and Roferon-A(r): A Southwest Oncology Group study. *Cancer Biotherapy* 9:301-306, 1994.
12. Poplin EA, **Tangen CM**, Harvey WH, Macdonald JS. Hepatoma/merbarone. *Invest New Drug* 12:337-340, 1994.
13. Berenberg J, **Tangen C**, Macdonald JS, Hutchins LF, Natale RB, Oishi N, Guy JT, Fleming T. Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer: A Southwest Oncology Group study. *Cancer* 76:715-719, 1995.
14. Leichman CG, Fleming TR, Muggia FM, **Tangen CM**, Ardalan B, Doroshow JH, Meyers FJ, Bickers JN, Weiss GR, Neidhard JA, Macdonald J. Phase II study of 5-FU and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study. *J Clin Oncol* 13:1303-1311, 1995.
15. Macdonald JS, Fleming TR, Peterson RF, Berenberg JL, McClure S, Chapman RA, Eyre HJ, Canefield V, Cruz AB, Gagliano R, **Tangen CM**, Rivkin S. Adjuvant chemotherapy with 5-FU,

- Adriamycin and Mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. *Ann Surg Oncol* 2:488-494, 1995.
16. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, **Tangen CM**, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. *J Clin Oncol* 13:2936-2943, 1995.
 17. Fabian C, Giri S, Estes N, **Tangen CM**, Poplin E, et al. Adjuvant continuous infusion 5FU, whole abdominal radiation and tumor bed boost in Dukes C2 colon carcinoma: A Southwest Oncology Group study. *International Journal of Radiation Oncology, Biology, Physics* 32:457-464, 1995.
 18. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, **Tangen CM**, et al. Fluorouracil plus levamisole as effective adjuvant therapy for resected stage III colon carcinoma: A final report. *Ann Intern Med* 122:321-326, 1995.
 19. Williamson SK, **Tangen CM**, Maddox AM, Spiridonidis CH, Macdonald JS. Phase II evaluation of low dose continuous 5-fluorouracil (5FU) and weekly cis-platinum (CDDP) in advanced adenocarcinoma of the stomach: A Southwest Oncology Group study. *Am J Clin Oncol* 18:484-487, 1995.
 20. Myeloma Trialists' Collaboration Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. *J Clin Oncol* 16(12):3832-3842, 1998.
 21. Goldberg RM, Fleming TR, **Tangen CM**, Moertel CG, Haller DG, Laurie JA. Surgery for recurrent colon cancer: Strategies for identifying resectable recurrence and success rates after resection. *Ann Intern Med* 129:27-35, 1998.
 22. Koch, GG, **Tangen CM**, Jung JW, Amara IA. Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and nonparametric strategies for addressing them. *Stat Med* 17:1863-1892, 1998.
 23. Hussain M, Petrylak D, Fisher E, **Tangen C**, Crawford D. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. *Seminars in Oncology* 26(5):55-60, 1999.
 24. Koch GG, **Tangen CM**. Nonparametric analysis of covariance and its role in non-inferiority clinical trials. *Drug Information Journal* 33(4):1145-1159, 1999.
 25. Schoen RE, **Tangen CM**, Kuller LH, Burke GL, Cushman M, Tracy RP, Dobs A, Savage PJ. Increased blood glucose and insulin, body size, and incident colorectal cancer. *J Natl Cancer Inst* 91(13):1147-1154, 1999
 26. Sloane PD, Davidson S, Knight N, **Tangen C**, Mitchell CM. Severe Disruptive Vocalizers, J. *American Geriatrics Society*, 47(4):439-445, 1999.
 27. **Tangen CM**, Koch GG. Nonparametric analysis of covariance for hypothesis testing with logrank and Wilcoxon scores and survival rate estimation in a randomized clinical trial. *J Biopharm Stat*, 9(2): 307-338, 1999.

28. **Tangen CM**, Koch GG. Complementary nonparametric analysis of covariance for logistic regression in a randomized clinical trial. *J Biopharm Stat* 9(1):45-66, 1999.
29. Aariyo A, Haan M, **Tangen C**, Rutledge JC, Cushman M, Dobs A, Furberg CD. Depressive symptoms and risk of coronary heart disease and mortality in elderly Americans. *Circulation* 102(15):1773-1779, 2000.
30. Yaffe K, Haan M, Byers A, **Tangen C**, and Kuller L. Estrogen use, APOE, and cognitive decline. *Neurology* 54:1949-1953, 2000.
31. **Tangen CM**, Koch GG. Nonparametric covariance methods for incidence density analysis of time-to-event data from a randomized clinical trial. *Statistics in Medicine* 19:1039-1058, 2000.
32. Thompson IM, **Tangen CM**, Tolcher A, Crawford ED, Eisenberger M, Moinpour CM. Re: Association of African-American ethnic background with survival in men with metastatic prostate cancer - Response. *JNCI* 93(15):1174-1175, 2001
33. **Tangen CM**, Koch GG. Nonparametric analysis of covariance for confirmatory randomized clinical trials to evaluate dose-response relationships. *Statistics in Medicine* 20:2585-2607, 2001.
34. Fried L, **Tangen C**, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: Evidence for a phenotype. *Journal of Gerontology* 56A(3):M146-M156, 2001.
35. Powell IJ, **Tangen CM**, Miller GJ, Lowe BA, Haas G, Carroll PR, Osswald MB, deVere White R, Thompson IM, Crawford ED. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, phase II Southwest Oncology Group Study 9109. *J Urol* 168:2016-2019, 2002.
36. Gatenby RA, Gawlinski ET, **Tangen CM**, Flanigan RC, Crawford ED. The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. *Cancer Res* 62:5218-5222, 2002.
37. Klein CE, **Tangen CM**, Braun TJ, Hussain MHA, Peereboom DM, Nichols CR, Rivkin SE, Dakhil SR, Crawford ED. SWOG-9510: Evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group Study. *Prostate* 52:264-268, 2002.
38. Thompson IM, **Tangen C**, Basler J, Crawford ED. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. *J Urol* 168:1008-1012, 2002.
39. Kop WJ, Gottdiener JS, **Tangen CM**, Fried LP, McBurnie MA, Walston J, Newman A, Hirsch C, and Tracy RP. Inflammation and coagulation factors in persons >65 years of age with symptoms of depression but without evidence of myocardial ischemia. *American Journal of Cardiology* 89(4):419-424, 2002.
40. **Tangen CM**, Faulkner JR, Crawford ED, Thompson IM, Hirano D, Eisenberger M, Hussain M. Ten-year survival in patients with metastatic prostate cancer. *Clin Prostate Cancer* 2(1):41-45, 2003.

41. Grossman HB, Natale RB, **Tangen CM**, Speights VO, Vogelzang NJ, Trump DL, devere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *N Engl J Med* 349(9):859-866, 2003.
42. Thompson IM, Goodman PJ, **Tangen CM**, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. *N Engl J Med* 349(3):215-224, 2003.
43. Thompson IM, **Tangen C**, Goodman P. The prostate cancer prevention trial: design, status, and promise. *World J Urol* 21:28-30, 2003.
44. Glass TR, **Tangen CM**, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. *J Urol* 169(1):164-169, 2003.
45. Higano C, Shields A, Wood N, Brown J, **Tangen C**. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. *Urology* 64(6):1182-1186, 2004.
46. Beer TM, **Tangen CM**, Bland LB, Thompson IM, Crawford ED. Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group Study 8894. *J Urol* 172:2213-2217, 2004.
47. Petrylak DP, **Tangen CM**, Hussain MHA, Lara PN, Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N Engl J Med* 351(15):1513-1520, 2004.
48. Flanigan RC, Mickisch G, Sylvester R, **Tangen C**, Van Poppel H, ED Crawford. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. *J Urol* 171:1071-1076, 2004.
49. Thompson IM, Pauler DK, Goodman PJ, **Tangen CM**, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. *N Engl J Med* 350(22):2239-2246, 2004.
50. Goodman PJ, **Tangen CM**, Crowley JJ, Carlin SM, Ryan A, Coltman CA Jr, Ford LG, Thompson IM. Implementation of the Prostate Cancer Prevention Trial (PCPT). *Control Clin Trials* 25:203-222, 2004.
51. **Tangen CM**, Goodman PJ, Crowley JJ, Thompson IM. Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. *J Urol* 171:S64-S67, 2004.
52. Thompson IM, **Tangen CM**, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. *JAMA* 294(23):2996-3002, 2005.

53. Hussain M, **Tangen CM**, Lara PN, Jr, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA, Crawford ED. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group Trial S0111. *J Clin Oncol* 23(24):8724-8729, 2005.
54. Sarosdy MF, **Tangen CM**, Weiss GR, Nestok BR, Benson MC, Schellhammer PF, Sagalowsky AI, Wood DP Jr, Crawford ED. A phase II clinical trial of oral bropiramine in combination with intravesical bacillus Camette-Guérin for carcinoma in situ of the bladder: A Southwest Oncology Group study. *Urol Oncol* 23(6):386-389, 2005.
55. Thompson IM, **Tangen CM**, Klein EA, Lippman SM. Phase III prostate cancer prevention trials: are the costs justified? *J Clin Oncol* 23(32):8161-8164, 2005.
56. Klein EA, **Tangen CM**, Goodman PJ, Lippman SM, Thompson IM. Assessing benefit and risk in the prevention of prostate cancer: the Prostate Cancer Prevention Trial revisited. *J Clin Oncol* 23(30):7460-7466, 2005.
57. Marshall JR, Sakr W, Wood D, Berry D, **Tangen C**, Parker F, Thompson I, Lippman SM, Lieberman R, Alberts D, Jarrard D, Coltman C, Greenwald P, Minasian L, Crawford ED. Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. *Cancer Epidemiol Biomarkers Prev* 15(8):1479-1484, 2006.
58. Grossman HB, **Tangen CM**, Cardon-Cardo C, Cote R, Waldman FM, deVere White, RW, Karnad AB, Glode M, Crawford ED. Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy. *Oncol Rep* 16(4):807-810, 2006.
59. Thompson IM, **Tangen CM**, Does prostate volume affect accurate grading of prostate biopsies? *Nat Clin Pract Uro* 3(6):298-299, 2006.
60. Thompson IM, **Tangen CM**, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer: result of a randomized prospective clinical trial. *JAMA* 296:2329-2335, 2006.
61. Silverman MH, **Tangen CM**. Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees. *Clin Trials* 3:313-319, 2006.
62. Dixon DO, Freedman RS, Herson J, Hughes M, Kim K, Silverman MH, **Tangen CM**. Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees. *Clin Trials* 3:313-319, 2006.
63. Hussain M, **Tangen CM**, Higano C, Schellhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). *J Clin Oncol* 24(24):3984-3990, 2006.
64. Petrylak DP, Ankerst D, Pauler, Jiang CS, **Tangen CM**, Hussain MHA, Lara PN, Jr, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Evaluation of

- prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. *J Natl Cancer Inst* 98(8):516-521, 2006.
65. Beer TM, **Tangen CM**, Nichols CR, Margolin KA, Dreicer R, Stephenson WT, Quinn DI, Raghavan D, Crawford ED. Southwest Oncology Group phase I study of arsenic trioxide in patients with refractory germ cell malignancies. *Cancer* 106(12):2624-2629, 2006.
66. Goodman PJ, Thompson IM, Jr, **Tangen CM**, Crowley JJ, Ford LG, Coltman CA, Jr. The Prostate Cancer Prevention Trial: design, biases and interpretation of study results. *Urology* 175:2234-2242, 2006.
67. Kristal AR, Chi C, **Tangen CM**, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. *Cancer* 106(2):320-328, 2006.
68. Thompson IM, Ankerst D Pauler, Chi C, Goodman PJ, **Tangen CM**, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. *J Natl Cancer Inst* 98(8):529-534, 2006.
69. Thompson IM, Chi C, Ankerst D Pauler, Goodman PJ, **Tangen CM**, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. *J Natl Cancer Inst* 98(16):1128-1133, 2006.
70. Beer TM, **Tangen CM**, Bland LB, Hussain M, Goldman BH, DeLoughery TG, Crawford ED. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer. *Cancer* 107(3):489-496, 2006.
71. Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, **Tangen CM**, et al. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group study. *Clin Cancer Res* 12(7):2178-2184, 2006.
72. Montgomery RB, Goldman B, **Tangen CM**, Hussain M, Petrylak DP, Page S, Klein EA, Crawford ED. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. *J Urol* 178:1946-1951, 2007.
73. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, **Tangen CM**, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. *J Natl Cancer Inst* 99(18):1375-1383, 2007.
74. Ryan CW, Goldman BH, Lara PN, Jr, Mack PC, Beer TM, **Tangen CM**, Lemmon D, Pan C-X, Drabkin HA, Crawford ED. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. *J Clin Oncol* 25(22):3296-3301, 2007. PMID: 17664477
75. Thompson IM, Ankerst DP, Chi C, Goodman PJ, **Tangen CM**, Lippman SM, Lucia MS, Parnes HL, Coltman CA, Jr. Prediction of prostate cancer for patients receiving finasteride: Results from the Prostate Cancer Prevention Trial. *J Clin Oncol* 25(21):3076-3081, 2007.
76. Cookson MS, Aus G, Burnett AL, Canby-Higano ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, **Tangen C**, Thrasher

- JB, Thompson I. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. *J Urol* 177:540-545, 2007.
77. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Higano ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, **Tangen CM**. Guideline for the management of clinically localized prostate cancer: 2007 update. *J Urol* 177:2106-2131, 2007.
78. Lerner SP, **Tangen CM**, Sucharew H, Wood D, Crawford ED. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, Ta bladder cancer. *J Urol* 177:1727-1731, 2007.
79. Swanson GP, Hussey MA, **Tangen CM**, Chin J, Messing E, Canby-Higano E, Forman JD, Thompson IM, Crawford ED. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. *J Clin Oncol* 25(16):2225-2229, 2007.
80. Wolman SR, Goldman B, Slovak ML, **Tangen C**, Persons DL, Wood D. Aneusomy for detection of bladder cancer recurrence: a Southwest Oncology Group study. *Cancer Genet Cytogenet* 176:22-27, 2007.
81. Thompson IM, Lucia MS, **Tangen CM**. Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present. *Int J Epidemiol* 36(2):287-289, 2007.
82. Thompson IM, Jr, **Tangen CM**, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, Coltman CA, Jr. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. *J Urol* 177:1749-1752, 2007.
83. Swanson GP, Goldman B, **Tangen CM**, Chin J, Messing E, Canby-Higano E, Forman JD, Thompson IM, Crawford ED. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. *J Urol* 180:2453-2458, 2008. PMID: 18930488
84. Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, **Tangen C**, Parekh D, Leach RJ, Thompson I. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. *J Urol* 180:1303-1308, 2008. PMID: 18707724
85. Neuhaus ML, Schenk J, Song YJ, **Tangen CM**, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the Prostate Cancer Prevention Trial. *The Prostate* 68:1477-1486, 2008. PMID: 18618736. PMCID: PMC2564287
86. Song Y, **Tangen C**, Goodman P, L PH, Lucia MS, Thompson IM, Kristal AR. Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment. *The Prostate* 68:281-286, 2008. PMID: 18163420

87. Redman MW, **Tangen CM**, Goodman PJ, Lucia MS, Coltman CA, Jr, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. *Cancer Prev Res* 1(3):174-181, 2008.
88. Thompson IM, **Tangen CM**, Parnes HL, Lippman SM, Coltman CA, Jr. Does the level of prostate cancer risk affect cancer prevention with finasteride? *Urology* 71(5):854-857, 2008. PMID: 18455628. PMID: PMC2692669
89. Sartor AO, **Tangen CM**, Hussain MHA, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford ED. Antiandrogen withdrawal in castrate-refractory prostate cancer. *Cancer* 112(11):2393-2400, 2008. PMID: 18383517
90. Higano CS, **Tangen CM**, Sakr WA, Faulkner J, Rivkin SE, Meyers FJ, Hussain M, Baker LH, Russell KJ, Crawford ED. Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin. *Cancer* 112(10):2181-2187, 2008. PMID: 18404692
91. Thompson IM, **Tangen CM**, Ankerst DP, Chi C, Lucia MS, Goodman P, Parnes H, Coltman C A J. The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. *J Urol* 180:544-547, 2008.
92. Thompson IM, **Tangen CM**, Lucia MS. The Prostate Cancer Prevention Trial and the future of chemoprevention. *BJU Int* 101:933-934, 2008.
93. Thompson IM, **Tangen CM**, Kristal AR. Prostate-specific antigen: A misused and maligned prostate cancer biomarker. *JNCI* 100(21):1487-1488, 2008.
94. Flaig TW, **Tangen CM**, Hussain MHA, Stadler WM, Raghavan D, Crawford ED, Glodé LM. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. *J Clin Oncol* 26(9):1532-1536, 2008.
95. Schenk JM, Kristal AR, Neuhouser ML, **Tangen CM**, White E, Lin DW, Thompson IM. Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. *The Prostate* 69(12):1303-1311, 2009.
96. Gong Z, Kristal AR, Schenk JM, **Tangen CM**, Goodman PJ, Thompson IM. Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. *Cancer* 115(6):3661-3669, 2009.
97. Thompson IM, **Tangen CM**, Klein EA. Is there a standard of care for pathologic stage T3 prostate cancer? *J Clin Oncol*. 27(18):2898-9, 2009.
98. Crawford ED, **Tangen CM**. Clinical integration: laudable, but challenging. *Nat Rev Urol* 6(6):297-298, 2009.
99. Dorff TB, **Tangen CM**, Crawford ED, Petrylak DP, Higano CS, Raghavan D, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MHA. Cooperative group trials--Southwest Oncology Group (SWOG) innovations in advanced prostate cancer. *Ther Adv Med Oncol* 1(2):69-77, 2009.

100. Thompson IM, **Tangen CM**, Goodman PJ, Lucia MS, Klein EA. Chemoprevention of prostate cancer. *J Urol* 182(2):499-508, 2009.
101. Lara PN, Jr, **Tangen CM**, Conlon SJ, Flanigan RC, Crawford ED. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group trial S8949. *J Urol* 181(2):512-517, 2009.
102. Thompson IM, **Tangen CM**, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Higano E, Crawford ED. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. *J Urol* 181(3):956-962, 2009.
103. Lerner SP, **Tangen CM**, Sucharew H, Wood D, Crawford ED. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. *Urol Oncol* 27(2):155-159, 2009.
104. Hussain M, Goldman B, **Tangen C**, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, DiPaola RS, Crawford ED. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group trials 9346 (Intergroup study 0162) and 9916. *J Clin Oncol* 27(15):2450-2456, 2009.
105. deVere White RW, Lara PN, Jr, Goldman B, **Tangen CM**, Smith DC, Wood DP, Jr, Hussain MHA, Crawford ED. A sequential treatment approach to myoinvasive urothelial cancer: a Phase II Southwest Oncology Group trial (S0219). *J Urol* 181:2476-2481, 2009.
106. Thompson IM, **Tangen CM**, Goodman PJ, Lucia MS, Klein EA. Chemoprevention of prostate cancer. *J Urol* 182(2):499-508, 2009.
107. Goodman PJ, **Tangen CM**, Kristal AR, Thompson IM, Lucia MS, Platz EA, Figg WD, Hoque A, Hsing Neuhauser ML, Parnes HL, Reichardt JKV, Santella RM, Till C, Lippman SM. Transition of a clinical trial into translational research: the prostate Cancer Prevention Trial experience. *Cancer Prev Res* 3(12):1523-1533, 2010.
108. Hoque A, Ambrosone CB, Till C, Goodman PJ, **Tangen C**, Kristal A, Lucia S, Wang Q, Kappil M, Thompson I, Hsing AW, Parnes, H, Santella RM. Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial. *Cancer Prev Res* 3(4):478-483, 2010.
109. Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW, Reichardt JKV, Hoque A, **Tangen CM**, Kristal AR, Thompson IM, Figg WD. Androgen receptor CAG repeat length and association with prostate cancer risk: Results from the Prostate Cancer Prevention Trial. *J Urol* 184:2297-2302, 2010.
110. Schenk JM, Kristal AR, Neuhauser ML, **Tangen CM**, White E, Lin DW, Kratz M, Thompson IM. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. *Am J Epidemiol* 171(5):571-582, 2010. PMID: 20142396, PMCID: PMC2842217

111. Hoque A, Ambrosone CB, Till C, Goodman PJ, **Tangen C**, Kristal A, Lucia S, Wang Q, Kappil M, Thompson I, Hsing AW, Parnes H, Santella RM. Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial. *Cancer Prev Res* 3(4):478-483, 2010. PMID: 20332306; PMCID: PMC2853720
112. Petrylak DP, **Tangen CM**, Van Veldhuizen PJ, Jr, Goodwin JW, Twardowski PW, Atkins JN, Kakhil SR, Lange MK, Mansukhani M, Crawford ED. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. *BJU Int* 105(3):317-21, 2010. PMID: 19888985
113. Moodie PF, Saville BR, Koch GG, **Tangen CM**. Estimating covariate-adjusted log hazard ratios for multiple time intervals in clinical trials using nonparametric randomization based ANCOVA. *Statistics in Biopharmaceutical Research* 3(2):232-241, 2011
114. Solit DB, **Tangen C**, Lara PN, Jr. Developing and implementing more informative phase II oncology trials. *ASCO Educational Book*, 2011.
115. Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, deVere White RW, Vogelzang NJ, Trump DL, Natale RB, **Tangen CM**, Crawford ED, Thompson IM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of S8710. *BJU Int* 108(5):693-699, 2011.
116. Klein EA, Thompson IM, **Tangen CM**, et al. Vitamin E and the risk of prostate cancer. *JAMA* 306(14):1549-1556, 2011.
117. Tang L, Yao S, Till C, Goodman PJ, **Tangen CM**, UuY, Kristal AR, Platz EA, Neuhaus ML, Stanczyk FZ, Reichardt JKV, Santella RM, Hsing A, Hoque A, Lippman SM, Thompson IM, Ambrosone CB. Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial. *Carcinogenesis* 32(10):1500-1506, 2011.
118. Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, **Tangen CM**, et al. Serum estrogen levels and prostate cancer risk in the Prostate Cancer Prevention Trial: a nested case-control study. *Cancer Causes and Control* 22:1121-1131, 2011.
119. Schenk J, Arnold K, **Tangen C**, Neuhaus M, Lin D, White E, Thompson I, Kristal A. No Association of Symptomatic Benign Prostatic Hyperplasia and Prostate Cancer When Detection Bias is Minimized: Results From the Prostate Cancer Prevention Trial. *Am J Epidemiol* 173(12):1419-1428, 2011.
120. Smith DC, **Tangen CM**, Van Veldhuizen PJ, Harrer GW, Golshayan A, Mills GM, Vogelzang NJ, Thompson IM, Hussain MHA. Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination with Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma of the Prostate: Southwest Oncology Group (SWOG) S0032. *Urology* 77(5):1172-1176, 2011.
121. Dorff, TB, Flaig TW, **Tangen CM**, Hussain M, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson I, Glode LM. Adjuvant Androgen Deprivation for High Risk Prostate Cancer after Radical Prostatectomy: Southwest Oncology Group (SWOG) Study S9921. *J Clin Oncol* 29:2040-2045, 2011.

122. Vickers A, Till C, **Tangen CM**, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate specific antigen velocity in prostate cancer detection. *JNCI* 103(6):462-469, 2011.
123. Marshall J, **Tangen C**, Sakr W, Wood D, Berry D, Klein E, Lippman S, Parnes H, Alberts D, Jarrard D, Lee WR, Gaziano JM, Crawford ED, Ely B, Ray M, Davis W, Minasian LM, Thompson IM. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. *Cancer Prev Res* 4(11):1761-1769, 2011.
124. Kristal AR, Till C, **Tangen CM**, Goodman PJ, Neuhaus ML, Stanczyk FZ, Chu LW, Patel SK, Thompson IM, Reichardt JK, Hoque A, Platz EA, Figg WD, VanBokhoven A, Lippman SM, Hsing AW. Associations of serum sex steroid hormone and 5 α -androstane-3 α , 17 β -diol glucuronide concentrations with prostate cancer risk among men treated with finasteride. *CEBP* 21(10):1823-1832, 2012.
125. Lotan Y, Goodman PJ, Youssef RF, Svatek RS, Shariat SF, **Tangen CM**, Thompson IM, Klein EA. Evaluation of Vitamin E and selenium supplementation on the prevention of bladder cancer in SWOG-coordinated SELECT. *J Urology* 4S:e515-e516, 2012.
126. Schenk JM, Calip GS, **Tangen CM**, Goodman P, Parsons JK, Thompson IM, Kristal AR. Indications for and use of non-steroidal anti-inflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: Results from the Prostate Cancer Prevention Trial. *Amer J of Epi* 176(2):156-163, 2012.
127. Berglund RK, **Tangen CM**, Powell IJ, Lowe BA, Haas G, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP, Crawford ED, Thompson IM, Klein EA. Ten-Year follow-up of neoadjuvant therapy with goserelin acetate and flutamide prior to radical prostatectomy for clinical T3 and T4 prostate cancer: Update on SWOG study S9109. *Urology*. 79(3):633-7, 2012.
128. LeBlanc M, **Tangen C**. Choosing Phase II Endpoints and Designs: Evaluating the Possibilities. *Clin Cancer Res* 18:8 2130-2132, 2012.
129. **Tangen CM**, Hussain MHA, Higano CS, Eisenberger MA, Small EJ, Wilding G, et al. Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8894 & S9346). *J Urology* 188:1164-1169, 2012.
130. Thompson IM, **Tangen C**. Prostate Cancer: uncertainty and a way forward. *NEJM* 367:270-1, 2012.
131. Neuhaus ML, Platz E, Till C, **Tangen CM**, Goodman PJ, Kristal A, Parnes HL, Tao Y, Figg WD, Lucia MS, Hoque A, Hsing AW, Thompson IM, Pollak M. Insulin-like growth factors and insulin-like growth factor binding proteins and prostate cancer risk: Results from the PCPT. *Cancer Prev Res* 6(2):91—99, 2013.
132. Skinner EC, Goldman B, Sakr WA, Petrylak DP, Lenz HJ, Lee CT, Wilson SS, Benson M, Lerner SP, **Tangen CM**, Thompson IM. S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-Guérin. *J Urol* 190(4):1200-1204, 2013.

133. Brasky TM, Darke AK, Song X, **Tangen CM**, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes LH, Klein EA, Kristal AR. Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial. *JNCI* 105:1132-1141, 2013.
134. Ankerst D, Till C, Boeck A, Goodman P, **Tangen C**, Thompson I. The impact of prostate volume, number of biopsy cores, and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. *Journal of Urology* 190(1):70-76, 2013.
135. Goodman PJ, Hartline JA, **Tangen CM**, Crowley JJ, Minasian LM, et al. Moving a randomized clinical trial into an observational cohort. *Clin Trials* 10(1):131-142, 2013.
136. Vickers AJ, Sjoberg DD, Ankerst DP, **Tangen CM**, Goodman PJ, Thompson IM. The prostate cancer prevention trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome. *Cancer* 119:3007-3011, 2013.
137. Schenk JM, Hunter-Merrill R, Zheng Y, Etzioni R, Gulati R, **Tangen C**, Thompson IM, Kristal A. Should modest elevations in PSA, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia? *Amer J of Epi* 178(5):741-751, 2013.
138. Hussain M. **Tangen CM**. Berry DL. Higano CS. Crawford ED. Liu G. Wilding G. Prescott S, Sundaram SK. Small EJ. Dawson NA. Donnelly BJ. Venner PM. Vaishampayan UN. Schellhammer PF. Quinn DI. Raghavan D. Ely B. Moinpour CM. Vogelzang NJ. Thompson IM Jr. Intermittent versus continuous androgen deprivation in prostate cancer. *N Engl J Med*. 368(14):1314-25, 2013.
139. Quinn DI, **Tangen CM**, Hussain M, et al. Docetaxel and abiraterone compared to docetaxel and placebo for men with advanced castration resistant prostate cancer: S0421. *Lancet Oncology* 14:893-900, 2013.
140. Thompson IM, Goodman PJ, **Tangen CM**, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG. Long-term survival of participants in the Prostate Cancer Prevention Trial. *N Eng J Med* 369(7):603-610, 2013.
141. Kristal AR, Darke AK, Morris S, **Tangen CM**, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. *JNCI* 106(3):1-8, 2014.
142. Lara PN, Ely B, Quinn DI, Mack PC, **Tangen C**, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD. Serum biomarkers of bone metabolism in castration resistant prostate cancer patients with skeletal metastases. *JNCI* 106(4):1-9, 2014.
143. Goldkorn A, Ely B, Quinn DI, **Tangen CM**, et al. Circulating tumor cell counts are prognostic of overall survival in S0421: A phase III trial of docetaxel with or without abiraterone for metastatic castration resistant prostate cancer. *JCO* 32:1136, 1142, 2014.

144. Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group. Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies. *JNCI* 106(9):2014.
145. Figg WD, Chau CH, Price DK, Till C, Goodman PG, Cho Y, Varella-Garcia M, Reichardt J, **Tangen CM**, Leach RJ, van Bokhoven A, Thompson IM, Lucia MS. Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results from the Prostate Cancer Prevention Trial. *Urology* 84(1):127-131, 2014.
146. Platz EA, **Tangen CM**, Goodman PJ, Till C, Parnes HL, Figg WD, Albanes D, Neuhauser ML, Klein EA, Lucia MS, Thompson IM, Kristal AR. Statin drug use is not associated with prostate cancer risk in men who are regularly screened. *Journal of Urology* 192(2):379-384, 2014.
147. Ankerst DP, Till C, Boeck A, Goodman PJ, **Tangen CM**, Thompson IM. Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores and AUA symptom score. *Urology* 82(5):1076-1081, 2014.
148. Thompson IM, **Tangen CM**. Prostate cancer screening comes of age. *The Lancet* 384:2004-2005, 2014.
149. Christodouleas, JP, Baumann BC, He J, Hwang WT, Tucker KN, Bekelman JE, **Tangen CM**, Lerner SP, Guzzo TJ, Malkowicz, SB. Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. *Cancer* 120(8):1272-1280, 2014.
150. Schenk J, Till C, **Tangen C**, Goodman P, Song X, Torkko K, Kristal A, Peters U, Neuhauser M. Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. *CEBP* 23(8):1484-1493, 2014.
151. Gritz E, Arnold K, Moinpour C, Burton-Chase A, **Tangen C**, Probstfield J, See W, Lieber M, Caggiano V, Thomas S, Szczepanek C, Ryan A, Carlin S, Hill S, Goodman P, Padberg R, Minasian L, Meyskens F, Thompson IM. Factors associated with adherence to an end-of-study biopsy: lessons from the Prostate Cancer Prevention Trial. *CEBP* 23(8):1638-1648, 2014.
152. Gurel B, Lucia MS, Thompson IM, Goodman P, **Tangen C**, Kristal A, Parnes H, Lippman S, Sutcliffe S, Peskoe S, Drake C, Nelson W, DeMarzo A, Platz E. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. *CEBP* 23(5):847-56, 2014.
153. Cassano P, Guertin K, Kristal A, Ritchie K, Bertoia M, Arnold K, Crowley J, Martinez E, Darke A, **Tangen C**, Goodman P, Fowke J, Klein EA, Abdulkadir A. A functional variant in NKX3.1 associated with prostate cancer risk in the SELECT Trial. *Cancer Prev Research*, 7(9):950-957, 2014.
154. Kristal A, Till C, Song X, **Tangen CM**, Goodman PJ, Neuhauser M, Thompson IM. Meyskens F. Goodman G, Minasian L, Parnes H. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. *CEBP* 23(8):1494-504, 2014.
155. Arnold K, Hermos J, Anderson K, Minasian L, **Tangen CM**, Probstfield J, Cook E. Retention of black and white participants in the Selenium and Vitamin E Cancer Prevention Trial (S0000). *CEBP* 23(12):2895-2905, 2014.

156. Hoque A, Yao S, Till C, Kristal A, Goodman P, Hsing A, **Tangen C**, Platz E, Stanczyk F, Reichardt J, VanBokhoven A, Neuhaus M, Santella R, Figg W, Price D, Parnes H, Lippman S, Ambrosone C, Thompson I. Effect of finasteride on serum androstenedione and risk of prostate cancer within the Prostate Cancer Prevention Trial: differential effect on high and low grade disease. *Urology* 85(3):616-620, 2015.
157. Christen W, Glynn R, Gaziano J, **Tangen C**, Crowley J, Goodman P, Darke A, Lippman SM, Lad T, Bearden J, Goodman G, Minasian L, Thompson I, Blanke C, Klein E. Age-related cataract in a randomized trial of selenium and vitamin E in men: The SELECT Eye Endpoints (SEE) Study. *JAMA Ophthalmology*, 133(1):17-24, 2015.
158. Umbuhr M, Gurel B, Murtola T, Sutcliffe S, Peskoe S, **Tangen C**, Goodman P, Thompson IM, Lippman S, Lucia MS, Parnes H, Drake C, Nelson W, DeMarzo A, Platz E. Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng/mL, normal DRE, and negative for prostate cancer. *Prostate Cancer and Prostatic Diseases* 18:264-269, 2015.
159. Yu E, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath E, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang N, Quinn D, Cheng H, Plymate SR, Hussain M, **Tangen CM**, Thompson IM. A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. *J Clin Oncol* 33(14):1601-1608, 2015.
160. Chau C, Price D, Till C, Goodman P, Chen X, Leach R, Johnson-Pais T, Hsing A, Hoque A, **Tangen C**, Chu L, Parnes H, Schenk J, Reichardt J, Thompson I, Figg W. Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial. *PLOS ONE* DOI:10.1371/journal.pone.0126672 May 8, 2015.
161. Winchester D, Till C, Goodman P, **Tangen C**, Santella R, Leach R, Xu J, Zheng X, Thompson IM, Lucia MS, Lippman SM, Parnes H, Dluzniewski H, Isaacs W, De Marzo A, Drake C, Platz E. Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. *Prostate* 75(13):1403-1418, 2015.
162. Cassano PA; Guertin KA; Kristal AR; Ritchie KE; Bertoia ML; Arnold KB; Crowley JJ; Hartline J; Goodman PJ; **Tangen CM**; Minasian LM; Lippman SM; Klein E. A randomized controlled trial of vitamin E and selenium on rate of decline in lung function. *Respiratory Research*. 16:35, 2015.
163. Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, **Tangen CM**, Barlow WE, Blanke C, Thompson IM, Hussain M. Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. *JAMA Oncol*.23:1-9, 2015.
164. Goldkorn A, Ely B, **Tangen CM**, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Vogelzang NJ, Thompson IM, Cote RJ, Quinn DI. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial *Int'l J of Cancer* 136(8):1856-1862, 2015.
165. The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) ICECaP Working Group JNCI 107(12):djv261 doi:10.1093/inci/djv261. Minasian L, **Tangen CM**, Wickerham DL. Ongoing use of data and specimens from NCI-sponsored cancer prevention

- clinical trials in the Community Clinical Oncology program. *Seminars in Oncology* 42(5):748-763, 2015.
166. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Karim Fizazi, **Tangen CM**, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KM, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF, Small EJ. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. *J Clin Oncol* 34:1652-1659, 2016.
167. Hussain M, **Tangen C** (co-primary authors), Celestia Higano, Nicholas Vogelzang, and Ian Thompson. Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details *J Clin Oncol* 34:280-285, 2015
168. Winchester DA, Gurel B, Till C, Goodman P, **Tangen C**, Santella R, Paris-Johnson T, Leach R, Thompson IM, Xu J, Zheng S, Lucia MS, Lippmann S, Parnes H, Isaacs W, Drake C, DeMarzo A, Platz E. Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the PCPT. *Prostate* 76(6):565-574, 2016.
169. LeBlanc M; **Tangen C**. Surrogates for Survival or Other End Points in Oncology. *JAMA Oncology* (2):263-264, 2016.
170. Travis RC; Appleby PN; Martin RM; Holly JM; Albanes D; Black A; Bueno-de-Mesquita HB; Chan JM; Chen C; Chirlaque MD; Cook MB; Deschasaux M; Donovan JL; Ferrucci L; Galan P; Giles GG; Giovannucci EL; Gunter MJ; Habel LA; Hamdy FC; Helzlsouer KJ; Hercberg S; Hoover RN; Janssen JA; Kaaks R; Kubo T; Le Marchand L; Metter EJ; Mikami K; Morris JK; Neal DE; Neuhauser ML; Ozasa K; Palli D; Platz EA; Pollak MN; Price AJ; Roobol MJ; Schaefer C; Schenk JM; Severi G; Stampfer MJ; Stattin P; Tamakoshi A; **Tangen CM**; Touvier M; Wald NJ; Weiss NS; Ziegler RG; Key TJ; Allen NE; Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group. A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. *Cancer Research*. 76(8):2288-300, 2016.
171. Schenk JM; Till C; Hsing AW; Stanczyk FZ; Gong Z; Neuhauser ML; Reichardt JK; Hoque AM; Figg WD; Goodman PJ; **Tangen CM**; Thompson IM. Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. *Cancer Causes & Control*. 27(2):175-82, 2016.
172. Unger JM; Till C. Thompson IM, Jr. **Tangen CM**, Goodman PJ. Wright JD, Barlow WE, Ramseny SD. Minasian LM, Hershman DL. Long-term consequences of finasteride vs placebo in the Prostate Cancer Prevention Trial. *J Natl Cancer Inst* 108 (12):djw168, 2016.
173. Chan JM, Darke A, Penney KL, **Tangen C**, Goodman P, Lee G-SM, Sun T, Peisch S, Tinianow A, Rae JR, Klein EA, Thompson IM, Kantoff PW, Mucci LA. Selenium- or vitamin E –related gene variants, interaction with supplementation, and risk of high-grade prostate cancer in SELECT. *Cancer Epidemiol Biomarkers Prev* 25(7):1050-1058, 2016.
174. Hershman DL; Unger JM; Wright JD; Ramsey S; Till C; **Tangen CM**; Barlow WE; Blanke C; Thompson IM; Hussain M. Adverse Health Events Following Intermittent and Continuous

- Androgen Deprivation in Patients With Metastatic Prostate Cancer. *JAMA Oncology*. 2(4):453-61, 2016.
175. Winchester DA, Till C, Goodman PJ, **Tangen**, CM, Santella, RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, De Marzo AM, Drake CG, Platz EA. Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. *The Prostate* 77(8):908-919, 2017.
176. Lerner SP,, **Tangen CM**,, Quale DZ (approx. 40 authors). Summary and recommendations from the NCI's clinical trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer. *Bladder Cancer* 2 165–201, 2016.
177. Chen H, Liu X, Brendler C, Ankerst D, Leach, R Goodman P, Lucia MS, **Tangen C**, Wang L, Hsu F-C, Sun J, Kader A, Isaacs W, Helf B, Zheng S, Thompson I, Platz E, Xu J. Adding Genetic Risk Score to Family History Identifies Twice as Many High-Risk Men for Prostate Cancer: Results From the Prostate Cancer Prevention Trial. *The Prostate* 76:1120–1129, 2016.
178. Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM, **Tangen CM**, Thompson IM, Reichardt JK, Figg WD. Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. *Cancer*. 122(15):2332-40, 2016.
179. Miles FL, Goodman PJ, **Tangen C**, Torkko KC, Schenk JM, Song X, Pollak M8, Thompson IM, Neuhouser ML Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. *Nutrients*. 9(4):378, 2017.
180. **Tangen CM**, Goodman PJ, Till C, Schenk JM, Lucia MS, Thompson IM, Jr. Biases in recommendations for and acceptance of prostate biopsy significantly affect assessment of prostate cancer risk factors: results from two large randomized clinical trials. *J Clin Oncol* 34:4338-4344. 2016
181. Chu LW, Till C, Yang B, **Tangen CM**, Goodman PJ, Yu K, Zhu Y, Han S, Hoque AM, Ambrosone C, Thompson I, Leach R, Hsing AW. Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. *Mol Carcinog*. 57(3):462-466, 2018.
182. Allen NE, Travis RC, et al, on behalf of the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group; Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies, *JNCI: Journal of the National Cancer Institute*, Volume 108(11):djw153, 2016.
183. Platz EA, Kulac I, Barber JR, Drake CG, Joshu CE, Nelson WG, Lucia MS, Klein EA, Lippman SM, Parnes HL, Thompson IM, Goodman PJ, **Tangen CM**, De Marzo AM. A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. *Cancer Epidemiol Biomarkers Prev*. 26(10):1549-1557, 2017..
184. Tang L, Platek ME, Yao S, Till C, Goodman PJ, **Tangen CM**, Wu Y, Platz Ea, Neuhouser ML, Stanczyk FZ, Reichardt JKV, Santella RM, Hsing A, Figg WD, Lippman SM, Thompson IM, Ambrosone CB. Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial *Carcinogenesis* 39(2):125–133, 2017.

185. Sonpavde G, Pond GR, Plets M, **Tangen CM**, Hussain M, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk P, Quinn DI. Validation of the association of RECIST changes with survival in men with metastatic castration resistant prostate cancer treated on SWOG study S0421. *Clin Genitourin Cancer* 15(6):635-641, 2017.
186. Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, ... **Tangen CM**..., Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, KoteJarai Z. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. *Nat Commun.* 9:1-19, 2018.
187. Watts EL, Appleby PN, Perez-Cornago A, Bueno-de-Mesquita HB, Chan JM, Chen C, Cohn BA, Cook MB, Flicker L, Freedman ND, Giles GG, Giovannucci E, Gislefoss RE, Hankey GJ, Kaaks R, Knekt P, Kolonel LN, Kubo T, Le Marchand L, Luben RN, Luostarinen T, Männistö S, Metter EJ, Mikami K, Milne RL, Ozasa K, Platz EA, Quirós JR, Rissanen H, Sawada N, Stampfer M, Stanczyk FZ, Stattin P, Tamakoshi A, **Tangen CM**, Thompson IM, Tsilidis KK, Tsugane S, Ursin G, Vatten L, Weiss NS, Yeap BB, Allen NE, Key TJ, Travis RC. Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies. *Eur Urol.* 74(5):585-594, 2018.
188. Schumacher FR, Al Olama AA, Berndt SI, ... **Tangen CM**, ... , Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nat Genet.* 50:928-936, 2018.
189. Unger JM, Hershman DL, Till C, **Tangen CM**, Barlow WE, Ramsey SD, Goodman PJ, Thompson IM. Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial, *JNCI* 110(11):1208-1215, 2018.
190. Messing EM, **Tangen CM**, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson IM. Effect of Intravesical Instillation of G 1 emcitabine vs Saline Immediately Following Resection of Suspected Low Grade Non-Muscle Invasive Bladder Cancer on Tumor Recurrence; SWOG S0337 Randomized Clinical Trial. *JAMA* 319(18):1880-1888, 2018.
191. Hussain M, **Tangen CM**, Thompson, IM Jr, Swanson GP, Wood DP, Sakr W, Dawson NA, Hass MB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM. Phase III Intergroup Trial of Adjuvant Androgen Deprivation with or without mitoxantrone plus prednisone in patients with High-Risk Prostate Cancer Post-Radical Prostatectomy: SWOG S9921. *J Clin Oncol* 36(15):1498-1504, 2018.
192. Svatek RS, **Tangen C**, Delacroix S, Lowrance W, Lerner SP. Background and update for S1602 “A Phase III randomized trial to evaluate the influence of BCG strain differences and T Cell priming with intradermal BCG before invasical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer”. *Eur Urol Focus* 4(4):522-524, 2018.
193. Thompson I Jr, Goodman P, **Tangen C**. Reduced Risk of Prostate Cancer With 5 α -Reductase Inhibitors. *J Natl Cancer Inst.* 110(11):1159, 1160, 2018.
194. James Y. Dai, Michael LeBlanc, Phyllis J. Goodman, M. Scott Lucia, Ian M. Thompson and **Catherine M. Tangen** Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men

- with Reduced Risk of High-grade Prostate Cancer by Finasteride. *Cancer Prev Res* 12(2):113-120, 2019.
195. **Tangen CM**, Schenk J, Till C, Goodman PJ, Barrington W, Lucia MS, Thompson IM. Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI. *Cancer Epidemiology* Vol 63, 2019, 101619, ISSN 1877-7821, <https://doi.org/10.1016/j.canep.2019.101619>.
196. Zhao YQ*, Zeng D, **Tangen CM**, LeBlanc ML. Robustifying Trial-Derived Treatment Rules to a Target Population. *Electronic Journal of Statistics* 2019 13(1):1717-1743.
197. Halabi S, Dutta S, **Tangen CM**, Rosenthal M, Petrylak DP, Thompson IM, Chi KM, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, Small EJ, Kelly WK. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel, *Journal of Clinical Oncology* 37(5): 403-410, 2019.
198. Archambault AN, Su Y-R, Jeon J, **Tangen CM**, Thibodeau SN, et al. Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. *Gastroenterology* 2020;158(5):1274–1286.e12. doi:10.1053/j.gastro.2019.12.012
199. Bull CJ, Bell JA, Murphy N, **Tangen CM**, Gunter MJ, et al. Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. *BMC medicine* 2020;18(1):396. doi:10.1186/s12916-020-01855-9
200. Halabi S, Dutta S, **Tangen CM**, Rosenthal M, et al. Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer. *Annals of oncology : official journal of the European Society for Medical Oncology* 2020;31(7):930–941. doi:10.1016/j.annonc.2020.03.309
201. Thomas M, Sakoda LC, Hoffmeister M, **Tangen CM**, He Q, et al. Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. *American journal of human genetics* 2020;107(3):432–444. doi:10.1016/j.ajhg.2020.07.006
202. McNabb S, Harrison TA, Albanes D, **Tangen CM**, et al. Meta-analysis of 16 studies of the association of alcohol with colorectal cancer. *International journal of cancer* 2020;146(3):861–873. doi:10.1002/ijc.32377
203. Papadimitriou N, Dimou N, Tsilidis KKK, **Tangen CM**, et al. Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. *Nature communications* 2020;11(1):597. doi:10.1038/s41467-020-14389-8
- 2021**
204. Conti DV, Darst BF, Moss LC, **Tangen CM**, Goodman PJ, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. *Nature genetics* 2021;53(1):65–75. doi:10.1038/s41588-020-00748-0
205. Thomas M, Sakoda LC, Hoffmeister M, **Tangen CM**, Huyghe JR, et al. Response to Li and Hopper. *American journal of human genetics* 2021;108(3):527–529. doi:10.1016/j.ajhg.2021.02.003
206. Pal SK, **Tangen C**, Thompson IM, Balzer-Haas N, et al. A comparison of sunitinib with

- cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. *Lancet* (London, England) 2021;397(10275):695–703.
207. Flaig TW, **Tangen CM**, Daneshmand S, Alva A, et al. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). *Clinical cancer research : an official journal of the American Association for Cancer Research* 2021. doi:10.1158/1078-0432.CCR-20-2409.
208. Goldkorn A, **Tangen C**, Plets M, Morrison GJ, et al.. Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). *Clinical cancer research : an official journal of the American Association for Cancer Research* 2021;27(7):1967–1973. doi: 10.1158/1078-0432.CCR-20-3587
209. Roshan A. Karunamuni, Minh-Phuong Huynh-Le, Chun C. Fan, Wesley Thompson, Rosalind A. Eeles, Zsofia Kote-Jarai, Kenneth Muir, Artitaya Lophatananon, Johanna Schleutker, Nora Pashayan, Jyotsna Batra, Henrik Grönberg, Eleanor I. Walsh, Emma L. Turner, Athene Lane, Richard M. Martin, David E. Neal, Jenny L. Donovan, Freddie C. Hamdy, Børge G. Nordestgaard, **Catherine M. Tangen**, Robert J. MacInnis, Alicja Wolk, Demetrius Albanes, Christopher A. Haiman, Ruth C. Travis, Janet L. Stanford, Lorelei A. Mucci, Catharine M. L. West, Sune F. Nielsen, Adam S. Kibel, Fredrik Wiklund, Olivier Cussenot, Sonja I. Berndt, Stella Koutros, Karina Dalsgaard Sørensen, Cezary Cybulski, Eli Marie Grindedal, Jong Y. Park, Sue A. Ingles, Christiane Maier, Robert J. Hamilton, Barry S. Rosenstein, Ana Vega, Manolis Kogevinas, Kathryn L. Penney, Manuel R. Teixeira, Hermann Brenner, Esther M. John, Radka Kaneva, Christopher J. Logothetis, Susan L. Neuhausen, Azad Razack, Lisa F. Newcomb, Marija Gamulin, Nawaid Usmani, Frank Claessens, Manuela Gago-Dominguez, Paul A. Townsend, Monique J. Roobol, Wei Zheng, Ian G. Mills, Ole A. Andreassen, Anders M. Dale, Tyler M. Seibert
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. **Prostate Cancer and Prostatic Diseases** 24(2) (2021)0108): 532-541
210. Xingyi Guo, Weiqiang Lin, Wanqing Wen, Jeroen Huyghe, Stephanie Bien, Qiuyin Cai, Tabitha Harrison, Zhishan Chen, Conghui Qu, Jiandong Bao, Jirong Long, Yuan Yuan, Fangqin Wang, Mengqiu Bai, Goncalo R Abecasis, Demetrius Albanes, Sonja I Berndt, Stéphane Bézieau, D Timothy Bishop, Hermann Brenner, Stephan Buch, Andrea Burnett-Hartman, Peter T Campbell, Sergi Castellví-Bel, Andrew T Chan, Jenny Chang-Claude, Stephen J Chanock, Sang Hee Cho, David V Conti, Albert de la Chapelle, Edith JM Feskens, Steven J Gallinger, Graham G Giles, Phyllis J Goodman, Andrea Gsur, Mark Ginter, Marc J Gunter, Jochen Hampe, Heather Hampel, Richard B Hayes, Michael Hoffmeister, Ellen Kampman, Hyun Min Kang, Temitope O Keku, Hyeon Rok Kim, Loic Le Marchand, Soo Chin Lee, Christopher I Li, Li Li, Annika Lindblom, Noralane Lindor, Roger L Milne, Victor Moreno, Neil Murphy, Polly A Newcomb, Deborah A Nickerson, Kenneth Offit, Rachel Pearlman, Paul D P Pharoah, Elizabeth A Platz, John D Potter, Gad Rennert, Lori C Sakoda, Clemens Schafmayer, Stephanie L Schmit, Robert E Schoen, Fredrick R Schumacher, Martha L Slattery, Yu-Ru Su, **Catherine M Tangen**, Cornelia M Ulrich, Franzel JB van Duijnhoven, Bethany Van Guelpen, Kala Visvanathan, Pavel Vodicka, Ludmila Vodickova, Veronika Vymetalkova, Xiaolong Wang, Emily White, Alicja Wolk, Michael O Woods, Graham Casey, Li Hsu, Mark A Jenkins, Stephen B Gruber, Ulrike Peters, Wei Zheng.
Identifying novel susceptibility genes for colorectal cancer risk from a transcriptome-wide association study of 125,478 subjects. **Gastroenterology** 160(4) (2021): 1164-1178.e6
211. Minh-Phuong Huynh-Le, Chun Chieh Fan, Roshan Karunamuni, Wesley K Thompson, Maria Elena Martinez, Rosalind A Eeles, Zsofia Kote-Jarai, Kenneth Muir, Johanna Schleutker, Nora Pashayan, Jyotsna Batra, Henrik Grönberg, David E Neal, Jenny L Donovan, Freddie C Hamdy, Richard M Martin, Sune F Nielsen, Børge G Nordestgaard, Fredrik Wiklund, **Catherine M**

- Tangen**, Graham G Giles, Alicja Wolk, Demetrius Albanes, Ruth C Travis, William J Blot, Wei Zheng, Maureen Sanderson, Janet L Stanford, Lorelei A Mucci, Catharine M L West, Adam S Kibel, Olivier Cussenot, Sonja I Berndt, Stella Koutros, Karina Dalsgaard Sørensen, Cezary Cybulski, Eli Marie Grindedal, Florence Menegaux, Kay-Tee Khaw, Jong Y Park, Sue A Ingles, Christiane Maier, Robert J Hamilton, Stephen N Thibodeau, Barry S Rosenstein, Yong-Jie Lu, Stephen Watya, Ana Vega, Manolis Kogevinas, Kathryn L Penney, Chad Huff, Manuel R Teixeira, Luc Multigner, Robin J Leach, Lisa Cannon-Albright, Hermann Brenner, Esther M John, Radka Kaneva, Christopher J Logothetis, Susan L Neuhausen, Kim De Ruyck, Hardev Pandha, Azad Razack, Lisa F Newcomb, Jay H Fowke, Marija Gamulin, Nawaid Usmani, Frank Claessens, Manuela Gago-Dominguez, Paul A Townsend, William S Bush, Monique J Roobol, Marie-Élise Parent, Jennifer J Hu, Ian G Mills, Ole A Andreassen, Anders M Dale, Tyler M Seibert, UKGPCS collaborators , APCB (Australian Prostate Cancer BioResource) , NC-LA PCaP Investigators , IMPACT Study Steering Committee and Collaborators , Canary PASS Investigators , Profile Study Steering Committee , PRACTICAL Consortium. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. **Nature communications** **12(1)** (20210223): 1236
212. Kristina M. Jordahl, Anna Shcherbina, Andre E. Kim, Yu-Ru Su, Yi Lin, Jun Wang, Conghui Qu, Demetrius Albanes, Volker Arndt, James W. Baurley, Sonja I. Berndt, Stephanie A. Bien, D. Timothy Bishop, Emmanouil Bouras, Hermann Brenner, Daniel D. Buchanan, Arif Budiarto, Peter T. Campbell, Robert Carreras-Torres, Graham Casey, Tjeng Wawan Cenggoro, Andrew T. Chan, David V. Conti, Christopher H. Dampier, Matthew A. Devall, Virginia Díez-Obrero, Niki Dimou, David A. Drew, Jane C. Figueiredo, Steven Gallinger, Graham G. Giles, Stephen B. Gruber, Andrea Gsur, Marc J. Gunter, Heather Hampel, Sophia Harlid, Tabitha A. Harrison, Akihisa Hidaka, Michael Hoffmeister, Jeroen R. Huyghe, Mark A. Jenkins, Amit D. Joshi, Temitope O. Keku, Susanna C. Larsson, Loic Le Marchand, Juan Pablo Lewinger, Li Li, Bharuno Mahesworo, Victor Moreno, John L. Morrison, Neil Murphy, Hongmei Nan, Rami Nassir, Polly A. Newcomb, Mireia Obón-Santacana, Shuji Ogino, Jennifer Ose, Rish K. Pai, Julie R. Palmer, Nikos Papadimitriou, Bens Pardamean, Anita R. Peoples, Paul D.P. Pharoah, Elizabeth A. Platz, John D. Potter, Ross L. Prentice, Gad Rennert, Edward Ruiz-Narvaez, Lori C. Sakoda, Peter C. Scacheri, Stephanie L. Schmit, Robert E. Schoen, Martha L. Slattery, Mariana C. Stern, **Catherine M. Tangen**, Stephen N. Thibodeau, Duncan C. Thomas, Yu Tian, Konstantinos K. Tsilidis, Cornelia M. Ulrich, Franzel J.B. van Duijnhoven, Bethany Van Guelpen, Kala Visvanathan, Pavel Vodicka, Emily White, Alicja Wolk, Michael O. Woods, Anna H. Wu, Natalia Zemlianskaia, Jenny Chang-Claude, W. James Gauderman, Li Hsu, Anshul Kundaje, Ulrike Peters. Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region. **Cancer Epidemiology, Biomarkers & Prevention**(20220419)
213. Jiayi Xu, Kristin A Guertin, Nathan C Gaddis, Anne H Agler, Robert S Parker, Jared M Feldman, Alan R Kristal, Kathryn B Arnold, Phyllis J Goodman, **Catherine M Tangen**, Dana B Hancock, Patricia A Cassano. Change in plasma α -tocopherol associations with attenuated pulmonary function decline and with CYP4F2 missense variation. **The American journal of clinical nutrition** **115(4)** (20220401): 1205-1216.
214. Xiang Shu, Zhishan Chen, Jirong Long, Xingyi Guo, Yaohua Yang, Conghui Qu, Yoon-Ok Ahn, Qiuyin Cai, Graham Casey, Stephen B Gruber, Jeroen R Huyghe, Sun Ha Jee, Mark A Jenkins, Wei-Hua Jia, Keum Ji Jung, Yoichiro Kamatani, Dong-Hyun Kim, Jeongseon Kim, Sun-Seog Kweon, Loic Le Marchand, Koichi Matsuda, Keitaro Matsuo, Polly A Newcomb, Jae Hwan Oh, Jennifer Ose, Isao Oze, Rish K Pai, Zhi-Zhong Pan, Paul D P Pharoah, Mary C Playdon, Ze-Fang Ren, Robert E Schoen, Aesun Shin, Min-Ho Shin, Xiao-Ou Shu, Xiaohui Sun, **Catherine M Tangen**, Chizu Tanikawa, Cornelia M Ulrich, Fränzel J B van Duijnhoven, Bethany Van

- Guelpen, Alicja Wolk, Michael O Woods, Anna H Wu, Ulrike Peters, Wei Zheng. Large-scale integrated analysis of genetics and metabolomic data reveals potential links between lipids and colorectal cancer risk. *CEBP* (20220310)
215. Fernandez-Rozadilla C, Timofeeva M, Chen Z, ...**Tangen C**..., Peters U. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. *Nat Genet.* 2023 Jan;55(1):89-99. doi: 10.1038/s41588-022-01222-9. PMID: 36539618
216. Agarwal N, **Tangen CM**, Hussain MHA, Gupta S, Plets M, Lara PN, Harzstark AL, Twardowski PW, Paller CJ, Zylla D, Zibelman MR, Levine E, Roth BJ, Goldkorn A, Vaena DA, Kohli M, Crispino T, Vogelzang NJ, Thompson IM Jr, Quinn DI. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). *J Clin Oncol.* 2022 Oct 1;40(28):3301-3309. doi: 10.1200/JCO.21.02517.
217. Lin HY, Tseng TS, Wang X, Fang Z, Zea AH, Wang L, Pow-Sang J, **Tangen CM**, Goodman PJ, Wolk A, Håkansson N, Kogevinas M, Llorca J, Brenner H, Schöttker B, Castela JE, Gago-Dominguez M, Gamulin M, Lessel D, Claessens F, Joniau S, The Practical Consortium, Park JY. Intake Patterns of Specific Alcoholic Beverages by Prostate Cancer Status. *Cancers (Basel).* 2022 Apr 14;14(8):1981. doi: 10.3390/cancers14081981.
218. Huynh-Le MP, Karunamuni R, Fan CC, Asona L, ... **Tangen CM**,Seibert TM. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. *Prostate Cancer Prostatic Dis.* 2022 Apr;25(4):755-761. doi: 10.1038/s41391-022-00497-7.
219. Gong Z, Platek ME, Till C, Goodman PJ, **Tangen CM**, Platz EA, Neuhaus ML, Thompson IM, Santella RM, Ambrosone CB. Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. *Front Oncol.* 2022 Jan 14;11:808715. doi: 10.3389/fonc.2021.808715.
220. Karunamuni RA, Huynh-Le MP, Fan CC, Thompson W, L... **Tangen CM**, Seibert TM. Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24 Prostate Cancer. *Prostatic Dis.* 2022 Feb;25(2):229-237. doi: 10.1038/s41391-021-00403-7.
221. Xu J, Guertin KA, Gaddis NC, Agler AH, Parker RS, Feldman JM, Kristal AR, Arnold KB, Goodman PJ, **Tangen CM**, Hancock DB, Cassano PA. Change in plasma α -tocopherol associations with attenuated pulmonary function decline and with CYP4F2 missense variation. *Am J Clin Nutr.* 2022 Apr 1;115(4):1205-1216. doi: 10.1093/ajcn/nqac013.
222. Jordahl KM, Shcherbina A, Kim AE, ...**Tangen CM**,... Peters U. Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region. *Cancer Epidemiol Biomarkers Prev.* 2022 May 4;31(5):1077-1089. doi: 10.1158/1055-9965.EPI-21-1003.
223. Schenk JM, Till C, Neuhaus ML, Goodman PJ, Lucia MS, Thompson IM, **Tangen CM**. Differential Biopsy Patterns Influence Associations between Multivitamin Use and Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial. *Cancer Epidemiol Biomarkers Prev.* 2022 Nov 2;31(11):2063-2069. doi: 10.1158/1055-9965.EPI-22-0453.
224. Shu X, Chen Z, Long J, Guo X, Yang Y, ...**Tangen CM**,, Peters U, Zheng W. Large-scale Integrated Analysis of Genetics and Metabolomic Data Reveals Potential Links Between Lipids and

- Colorectal Cancer Risk. *Cancer Epidemiol Biomarkers Prev.* 2022 Jun 1;31(6):1216-1226. doi: 10.1158/1055-9965.EPI-21-1008.
225. Thomas M, Su YR, Rosenthal EA, Sakoda LC, Schmit SL, ... **Tangen CM**, ..., Peters U, Hsu L. Combining Asian-European Genome-Wide Association Studies of Colorectal Cancer Improves Risk Prediction Across Race and Ethnicity. *medRxiv.* 2023 Jan 19:2023.01.19.23284737. doi: 10.1101/2023.01.19.23284737. Preprint.
226. Carreras-Torres R, Kim AE, Lin Y, Díez-Obrero V, Bien SA, ... **Tangen CM**, ... Hsu L, Peters U, Moreno V, Gauderman WJ. Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response. *Cancer Epidemiol Biomarkers Prev.* 2023 Mar 6;32(3):315-328. doi: 10.1158/1055-9965.EPI-22-0763.
227. Lara PN, Mayerson E, Gertz E, **Tangen C**, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Vogelzang NJ, Thompson I, Agarwal N. Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. *European Urology*, 2023, ISSN 0302-2838,
228. Flaig TW, **Tangen CM**, Daneshmand S, Alva AS, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM, Jr, Lerner SP. Long term outcomes from a phase II study of neoadjuvant chemotherapy for muscle invasive bladder cancer (SWOG S1314; NCT02177695). *European Urology* 2023 Sep;84(3):341-347.
229. Bhasin S, Travison TG, Pencina KM, O'Leary M, Cunningham GR, Lincoff AM, Nissen SE, Lucia MS, Preston MA, Khera M, Khan N, Snabes MC, Li X, **Tangen CM**, Buhr KA, Thompson IM Jr. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. *JAMA Netw Open.* 2023 Dec 1;6(12):e2348692.
230. Black PC, **Tangen CM**, Singh P, McConkey DJ, Lucia MS, Lowrance WT, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bankgs R, Plets M, Thompson IM, Lerner SP. Phase II trial of atezolizumab in BCG-unresponsive high-risk non-muscle invasive bladder cancer: SWOG S1605. *European Urology* 2023 Dec;84(6):536-544.
231. Ryan CW, **Tangen CM**, Heath EI, Stein MN, Meng MV, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo RG, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Thompson IM, Lara PN. Adjuvant everolimus after surgery for renal-cell carcinoma (EVEREST): A double-blind, placebo-controlled, randomized Phase 3 Trial. *Lancet* 2023; 402: 1043–51.
232. Sun G, Dizon DS, Szczepanek CM, Petrylak DP, Sparks DB, **Tangen C**, Lara, PN, Thompson IM, Blanke CD. Crisis of the clinical trials staff attrition following the Covid-19 pandemic. *JCO Oncology Practice* 2023;19(8):533-535.
233. Parikh M, **Tangen C**, Hussain MHA, Gupta S, Jo Y, Harzstark A, Callis S, Jo Y, Harzstark A, Paller CJ, George S, Zibelman MR, Cheng H, Maughan BL, Zhang J, Pachynski R, Bryce AH, Lin DW, Quinn DI, Lerner SP, Thompson IM, Dorff TB, Lara PN, Agarwal N. Three- and Seven-month Prostate-Specific Antigen Levels as Prognostic Markers for Overall Survival (OS) in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. In press, *European Urology Oncology*, accepted March 1, 2024.

234. Lara PN, **Tangen CM**, Heath EI, Stein MN, Meng M, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo R, Haas NB, Plets M, Vaishampayan UN, Shuch BM, Thompson IM, Ryan CW. Adjuvant everolimus in patients with completely resected very high-risk renal cell cancer and clear cell histology: results from the phase III placebo-controlled SWOG S0931 (EVEREST) trial, in press *European Urology*, April 2024.
235. Halabi S, Roy A, Rydzewska L, Guo S, Godolphin P, Hussain M, **Tangen C**, Thompson I, Xie W, Carducci MA, Smith MR, Morris MJ, Gravis G, Dearnaley DP, Verhagen P, Goto T, James N, Buyse ME, Tierney JF, Sweeney C; STOPCAP/ICECaP Collaboration. Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer. *J Clin Oncol*. 2024 Mar 20;42(9):1044-1054. doi: 10.1200/JCO.23.01535. Epub 2024 Jan 5.
236. Lerner SP, McConkey DJ, **Tangen CM**, Meeks JJ, Flaig TW, Hua X, Daneshmand S, Alva AS, Lucia MS, Theodorescu D, Goldkorn A, Milowsky MI, Choi W, Bangs R, Gustafson DL, Plets M, Thompson IM. Association of molecular subtypes with pathologic response, PFS and OS in a Phase II study of muscle-invasive bladder cancer (SWOG S1314; NCT 02177695). *Clinical Cancer Research* 2024;30(2):444-449.
237. Lara P, Mayerson E, Gertz E, **Tangen C**, Goldkorn A, Van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Przemyslaw Twardowski, David Quinn, Michael LeBlanc, Ian Thompson, and Neeraj Agarwal Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): a subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. *Prostate Cancer and Prostatic Diseases*, 27(3), 566-570 (2024).
238. Lerner SP, **Tangen C**, Svatek RS, Daneshmand S, Pohar KS, Skinner E, Schuckman A, Sagalowsky AI, Smith ND, Kamat AM, Kassouf W, Plets M, Bangs R, Koppie TM, Alva A, La Rosa, FG, Pal SK, Kibel AS, Canter DJ, Thompson IM. SWOG S1011 - A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer. *N Engl J Med* 2024;391:1206-1216.
239. Plimack ER, **Tangen C**, Plets M, Kokate R, Xiu J, Nabhan C, Ross EA, Grundy E, Choi W, Dinney CPN, Lee IC, Fong M, Lucia MS, Daneshmand S, Theodorescu D, Goldkorn A, Lerner SP, Flaig TW, McConkey DJ. S1314 correlative analysis of ATM, RB1, ERCC2 and FANCC mutations and pathologic complete response after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. *European Urology* Vol. 86(4): 297–300 (2024).
240. Barata P, **Tangen C**, Plets M, Thompson IM, Narayan V, George DJ, Heng DY, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason GA, Humphrey P, Adeniran A, Vaishampayan, U, Alva A, Zhang T, Cole S, Wright J, Lara, Jr., PN, Lerner SP, Balzer-Haas N, Pal SK. Final overall survival analysis of S1500: A randomized, phase II study comparing sunitinib to cabozantinib, crizotinib and savolitinib in advanced papillary renal cell carcinoma. *J Clin Oncol* 42:3911-3916 (2024).
241. Tripathi, A., **Tangen, C.M.**, Plets, M., Li, X., Tretiakova, M., Humphrey, P.A., Adeniran, A., Barata, P.C., Gulati, S., Bergerot, C.D., Pruthi, D.K., Thompson, I.M., Lara, P.N., Jr, Lerner, S.P., Pal, S.K. and Shuch, B.M. (2024), Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. *BJU Int* 2024; 134: 596–601.

242. Gulati S, **Tangen C**, Ryan CW, et al. Adjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Netw Open*. 2024;7(8):e2425288. doi:10.1001/jamanetworkopen.2024.25288.
243. Iyer G, **Tangen CM**, Sarfaty M, Regazzi AM, Lee I, Fong M, Choi W, Dinney CPN, Flaig TW, Thompson, Jr, IM, Lerner SP, McConkey DJ, Rosenberg JE. DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. *JCO Precision Oncol*, Vol 8 (2024) <https://doi.org/10.1200/PO.24.00287>.
244. Swami U, Jo Y, Narang A, Plets M, Chehade CH, Gebrael G, Gupta S, Myint Z, **Tangen C**, Lara Jr. PN, Thompson Jr. IM, Hussain MHA, Dorff TB, Lerner SP, Agarwal N. Correlation of body mass index with overall survival in patients with metastatic hormone-sensitive prostate cancer: Analysis of patient-level data from SWOG-1216 study. *Eur Urol Oncol* 2024 Nov 8:S2588-9311(24)00241-4. doi: 10.1016/j.euo.2024.10.013.
245. Gebrael G, Jo Y, Swami U, et al. Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial. *JAMA Netw Open*. 2024;7(7):e2419966. doi:10.1001/jamanetworkopen.2024.19966.
246. Unger JM, Till C, **Tangen CM**, et al. Long-Term Adverse Effects and Complications After Prostate Cancer Treatment. *JAMA Oncol*. 2024;10(12):1654–1662. doi:10.1001/jamaoncol.2024.4397

B. BOOK CHAPTERS

1. The Performance of PSA for Predicting Prostate Cancer After a Prior Negative Prostate Biopsy, Tangen C in *Prostate Cancer Screening, Second Edition*, 2009, Humana Press
2. Prostate-Specific Antigen and Its Role on the Prostate Cancer Prevention Trial, Tangen CM, Goodman PJ in *Prostate Cancer Screening, Second Edition*, 2009, Humana Press
3. Prostate Cancer, Tangen CM, Neuhaus ML, Stanford JL in *Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition*, Oxford University Press, 2018.
4. Managing a Portfolio of Trials, Tangen C, LeBlanc M in *Principles and Practice of Clinical Trials*, Springer first edition 2022
5. Phase II Trials Using Time to Event Endpoints, Tangen CM, Crowley J. in *Handbook of Statistics in Clinical Oncology, Fourth Edition*, Chapman and Hall, *Submitted to editors 2024*
6. Best Practices for Data Monitoring Committees, Tangen CM. in *Handbook of Statistics in Clinical Oncology, Fourth Edition*, Chapman and Hall, *submitted to editors 2024*
7. (Editing) *Prostate Cancer Screening*, Second Edition, Edited by Donna P. Ankerst, Catherine M. Tangen, Ian M. Thompson Jr, Humana Press, 2009

C. PUBLISHED BOOKS, VIDEO, SOFTWARE, etc, N/A

D. OTHER PUBLICATIONS N/A

E. Manuscripts Under Review

Bai Z, Osman M, Brendel M, Tangen CM, Flaig TW, Thompson IM, Plets M, Lucia MS, Theodorescu D, Gustafson D, Daneshmand S, Meeks JJ, Choi W, Dinney CPN, Elemento O, Lerner SP, McConkey DJ, Faltas BM, Wang F. Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning. January 2025

Apolo A, Baumann B, Al-Ahmadie H, ...**Tangen C**,.... Black PC. Summary and recommendations from the NCI Clinical Trials Planning Meeting on defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer. Bladder Cancer journal in press

8. DIVERSITY, EQUITY and INCLUSION ACTIVITIES

N/A

9. PROFESSIONAL ORGANIZATIONS

American Society of Clinical Oncology
American Statistical Association
Society for Clinical Trials
International Society for Clinical Biostatistics

10. EDUCATION AND TRAINING RESPONSIBILITIES

N/A

11. EDITORIAL RESPONSIBILITIES

2008-2014 Cancer Prevention Research Journal, Editorial Board
2014-2020 Journal of Clinical Oncology, Editorial Board

12. SPECIAL RESPONSIBILITIES AND SERVICE

A. International

N/A

B. National

2004-2007 Member, American Urologic Association, Guidelines for the Management of Clinically Localized Prostate Cancer
2008- Member, NCI Genitourinary Cancer Scientific Steering Committee
2018-2024 Member, NCI Cancer Prevention Scientific Steering Committee

C. Regional, SWOG Organization

1999- Genitourinary Committee Faculty Statistician
2005-2024 SWOG Statistical lead on Data and Safety Monitoring Committee
2006- Member of SWOG Conflict Management Committee
2013- Deputy Director, SWOG Statistics and Data Management Center
2013- SWOG Board of Governors
2013- SWOG Executive Committee
2014- SWOG NCORP m-PI
2013- PI, PCPT and SELECT Cancer Cohort U01
2018-2022 Member of EAB, Cancer Prevention Clinical Trials Network
2021- Prevention and Epidemiology Committee Faculty Statistician
2022- HOPE Foundation for Cancer Research Board Member (Exec Committee 2023 -)
2022- SWOG Executive Advisory Committee
2023 SWOG Chair nominating committee
2023 Genitourinary Committee Chair nominating committee

D. Local, Fred Hutchinson Cancer Center

Co-chair Clinical Trials Affinity Group 2014-2023
Member of promotion, recruitment and 5-year faculty review committees
Klorfine pilot study review chair 2022, 2023